This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| ABCC8 | |
|---|---|
| Name | ABCC8 |
| Altnames | SUR1 |
| Chromosome | 11p15.1 |
| Location | 11 |
| Family | ABC transporter family C |
ABCC8 is a human gene encoding the sulfonylurea receptor 1 protein, a regulatory subunit of the pancreatic ATP‑sensitive potassium (KATP) channel complex, involved in linking cellular metabolism to membrane excitability in pancreatic beta cells and other tissues. Disruption of ABCC8 function alters insulin secretion and is implicated in monogenic diabetes, congenital hyperinsulinism, and responsiveness to sulfonylurea drugs used in diabetes management. Research on ABCC8 spans molecular genetics, electrophysiology, pharmacology, and clinical therapeutics across basic and translational studies.
The protein encoded by this locus is a member of the ATP‑binding cassette transporter family C and assembles with a pore‑forming subunit to form the KATP channel; structural studies integrate cryo‑electron microscopy models, sequence data from the Human Genome Project, and homology with ABC transporters characterized at the European Molecular Biology Laboratory and the Salk Institute. High‑resolution structures reveal transmembrane domains and nucleotide‑binding folds that interact with ATP and ADP, analogous to mechanisms described for CFTR and MDR1; biochemical work from the Max Planck Institute and Cold Spring Harbor Laboratory has delineated ATP‑dependent conformational shifts that gate the associated potassium channel pore, similar to transport‑gating couplings reported for P‑glycoprotein. Functional assays using patch‑clamp techniques developed at institutions such as the University of Cambridge and Stanford University define conductance properties and gating kinetics modulated by intracellular nucleotides and pharmacological ligands.
Expression of the gene is highest in pancreatic islets, with developmental and tissue‑specific regulation mapped by transcriptomic atlases from the Broad Institute, ENCODE, and GTEx. Transcriptional regulation involves promoters and enhancers bound by islet transcription factors characterized at the Whitehead Institute, including factors studied in landmark works from Harvard Medical School and the University of Oxford; post‑transcriptional control includes RNA binding proteins and microRNAs explored in laboratories at Rockefeller University and the Karolinska Institutet. Epigenetic modulation, DNA methylation patterns reported by the Wellcome Sanger Institute, and chromatin remodeling at loci identified by the National Institutes of Health influence expression in response to metabolic and hormonal cues documented in clinical cohorts from Mayo Clinic and Mount Sinai.
In pancreatic beta cells, the protein forms a complex with the pore subunit to create KATP channels that couple cellular ATP/ADP ratios to membrane potential, a mechanism elucidated by physiological experiments at Columbia University and the University of Pennsylvania. Closure of these channels upon glucose metabolism depolarizes the membrane, triggering voltage‑gated calcium channel opening and insulin granule exocytosis, processes characterized in studies at the Karolinska Institutet, Johns Hopkins University, and University of California, San Diego. Comparative physiology studies referencing models from Kyoto University and University of Cambridge highlight conserved roles in glucose homeostasis across mammals and inform clinical interpretation at Cleveland Clinic and Imperial College London.
Loss‑ or gain‑of‑function variants in this locus produce clinical phenotypes ranging from congenital hyperinsulinism described in pediatric centers at Great Ormond Street Hospital to neonatal diabetes managed in adult endocrinology clinics at Massachusetts General Hospital and Royal Adelaide Hospital. Associations with type 2 diabetes susceptibility have been investigated in population studies from the Framingham Heart Study, UK Biobank, and the Nurses' Health Study. Clinical management paradigms incorporating genetic diagnosis, as implemented at the WellChild Clinic and the International Society for Paediatric and Adolescent Diabetes, guide transition from insulin therapy to oral sulfonylureas in mutation‑positive patients, a practice informed by trials at Guy's and St Thomas' NHS Foundation Trust and University of Toronto.
Pathogenic variants include missense, nonsense, splice‑site, and copy‑number changes cataloged in databases maintained by Genomics England, ClinVar, and DECIPHER; founder effects and recurrent mutations have been reported in cohorts assembled by the Human Genome Variation Society and the EuroGentest network. Functional characterization of variants uses heterologous expression systems and biochemical assays pioneered at institutions such as ETH Zurich and University College London; molecular pathogenesis models describe altered nucleotide binding, impaired channel trafficking to the plasma membrane, and aberrant gating consistent with studies from the Wellcome Trust Sanger Institute and Cold Spring Harbor Laboratory. Genotype–phenotype correlations have clinical prognostic value and inform family counseling practiced by genetic services at Stanford Children's Health and Boston Children's Hospital.
The protein is the pharmacological target of sulfonylureas and meglitinides developed by pharmaceutical companies and evaluated in trials at the National Institutes of Health Clinical Center, Royal Free Hospital, and Vanderbilt University Medical Center. Drug binding stabilizes conformations that promote channel closure to enhance insulin release; mechanistic drug‑binding data derive from structural pharmacology groups at the University of Cambridge and Pfizer Research. Precision medicine approaches, including genotype‑guided sulfonylurea therapy, have been implemented in clinics at University College London Hospitals and the Murdoch Children's Research Institute, while off‑target effects and channel modulators are assessed in preclinical pipelines at Novartis and AstraZeneca.
Experimental approaches include gene knockout and knock‑in mouse models developed at The Jackson Laboratory and EMBL, zebrafish models from the University of Geneva, and patient‑derived induced pluripotent stem cell beta‑cell models generated at the Salk Institute and Columbia University. Electrophysiology using patch‑clamp systems from Molecular Devices, high‑throughput screening platforms at the Broad Institute, and single‑cell transcriptomics methods from the Allen Institute underpin mechanistic studies. Collaborative consortia such as the International Human Epigenome Consortium and the Human Cell Atlas contribute datasets and standards used in ABCC8 research across academic centers including Yale University, Karolinska Institutet, and McGill University.
Category:Genes on human chromosome 11